[1]闫君娴隋晓军综述张晖**审校.自身免疫性胰腺炎诊断和治疗研究进展[J].中国微创外科杂志,2026,01(6):356-363.

点击复制

自身免疫性胰腺炎诊断和治疗研究进展()

参考文献/References:

[1]李兆申,李汛,郭晓钟,等.中国自身免疫性胰腺炎诊治指南(上海,2023).临床肝胆病杂志,2024,40(7):1312-1320.
[2]Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas,2011,40(3):352-358.
[3]de Pretis N, Carlin M, Calderini E, et al. Clinical features and long�瞭erm outcomes of patients with type 2 autoimmune pancreatitis. United European Gastroenterol J,2024,12(3):319-325.
[4]Dugic A, Verdejo Gil C, Mellenthin C, et al. The clinical utility of soluble serum biomarkers in autoimmune pancreatitis: a systematic review. Biomedicines,2022,10(7):1511.
[5]de Pretis N, Amodio A, De Marchi G, et al. The role of serological biomarkers in the diagnosis and management of autoimmune pancreatitis. Expert Rev Clin Immunol,2022,18(11):1119-1124.
[6]Xi W, Jiang Q, Bai X, et al. Predictive factors for relapse in autoimmune pancreatitis. Clin Transl Gastroenterol,2025,16(10):e00903.
[7]Jaber F, Elfert K, Alsakarneh S, et al. Clinical characteristics and outcomes of autoimmune pancreatitis based on serum immunoglobulin G4 levels: a single�瞔enter, retrospective cohort study. World J Gastroenterol,2023,29(47):6161-6164.
[8]Javed AA, Wright MJ, Ding D, et al. Autoimmune pancreatitis: a critical analysis of the surgical experience in an era of modern diagnostics. Pancreas,2021,50(4):556-563.
[9]Shih HC, Chang MC, Chen CH, et al. High accuracy differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma by immunoglobulin G glycosylation. Clin Proteomics,2019,16:1.
[10]Della Torre E, Mattoo H, Mahajan VS, et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4�瞨elated disease. Allergy,2014,69(2):269-272.
[11]Hara A, Watanabe T, Minaga K, et al. Biomarkers in autoimmune pancreatitis and immunoglobulin G4�瞨elated disease. World J Gastroenterol,2021,27(19):2257-2269.
[12]Caba O, Diéguez�睠astillo C, Martínez�睪alán J, et al. Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. World J Gastrointest Oncol,2023,15(2):268-275.
[13]Minaga K, Watanabe T, Hara A, et al. Identification of serum IFN�拨� and IL��33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4�瞨elated disease. Sci Rep,2020,10(1):14879.
[14]Lai Y, Shang M, Yang H, et al. Uncovering novel exosome�瞫pecific miRNA markers and potential molecular mechanisms in autoimmune pancreatitis. Genomics,2025,117(4):111068.
[15]周春华,邹多武.1型自身免疫性胰腺炎近十年研究进展和热点问题.中华内科杂志,2024,63(1):13-16.
[16]Ogawa H, Takehara Y, Naganawa S. Imaging diagnosis of autoimmune pancreatitis: computed tomography and magnetic resonance imaging. J Med Ultrason (2001),2021,48(4):565-571.
[17]Lee S, Kim JH, Kim SY, et al. Comparison of diagnostic performance between CT and MRI in differentiating non�瞕iffuse�瞭ype autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Eur Radiol,2018,28(12):5267-5274.
[18]Kwon JH, Kim JH, Kim SY, et al. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast�瞖nhanced MRI with special emphasis on the arterial phase. Eur Radiol,2019,29(11):5763-5771.
[19]Cho MK, Moon SH, Song TJ, et al. Contrast�瞖nhanced endoscopic ultrasound for differentially diagnosing autoimmune pancreatitis and pancreatic cancer. Gut Liver,2018,12(5):591-596.
[20]Datta D, Selvakumar B, Goel AD, et al. Diagnostic performance of F��18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: a systemic review and meta�瞐nalysis. Ann Nucl Med,2024,38(8):619-629.
[21]Elhanafi S, Mahmud N, Vergara N, et al. Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer. J Gastroenterol Hepatol,2019,34(5):907-913.
[22]Ozono Y, Kawakami H, Uchiyama N, et al. Current status and issues in genomic analysis using EUS�睩NA/FNB specimens in hepatobiliary�瞤ancreatic cancers. J Gastroenterol,2023,58(11):1081-1093.
[23]Notohara K, Kamisawa T, Kanno A, et al. Efficacy and limitations of the histological diagnosis of type 1 autoimmune pancreatitis with endoscopic ultrasound�瞘uided fine needle biopsy with large tissue amounts. Pancreatology,2020,20(5):834-843.
[24]Notohara K, Kamisawa T, Furukawa T, et al. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasound�瞘uided fine needle biopsy specimens: an interobserver agreement study. Virchows Arch,2022,480(3):565-575.
[25]Liu Y, Wan D, Wu C, et al. Endoscopic ultrasound�瞘uided fine�瞡eedle aspiration value in suspected autoimmune pancreatitis malignancy diagnosis. Cytojournal,2025,22:58.
[26]Kachi K, Naitoh I, Ban T, et al. Concomitant pancreatic ductal adenocarcinoma and type 1 autoimmune pancreatitis: a potential issue in the diagnosis of carcinoma by endoscopic ultrasound�瞘uided fine�瞡eedle biopsy. Intern Med,2023,62(4):545-551.
[27]Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4�瞨elated disease. Mod Pathol,2012,25:1181-1192.
[28]Yamashita, H, Naitoh, I, Nakazawa, T, et al. A comparison of the diagnostic efficacy in type 1 autoimmune pancreatitis based on biopsy specimens from various organs. Pancreatology,2014,14(3):186-192.
[29]Yoon SB, Moon SH, Kim JH, et al. The use of immunohistochemistry for IgG4 in the diagnosis of autoimmune pancreatitis: a systematic review and meta�瞐nalysis. Pancreatology,2020,20(8):1611-1619.
[30]Sano T, Kikuta K, Takikawa T, et al. Serum IgG4�瞡egative and IgG4�瞤ositive type 1 autoimmune pancreatitis present with different clinicopathological features: an analysis of a nationwide survey in Japan. Pancreatology,2025,25(1):82-88.
[31]Zen Y. Autoimmune pancreatitis: biopsy interpretation and differential diagnosis. Semin Diagn Pathol,2024,41(2):79-87.
[32]Zhang X, Liu X, Joseph L, et al. Pancreatic ductal adenocarcinoma with autoimmune pancreatitis�瞝ike histologic and immunohistochemical features. Hum Pathol,2014,45(3):621-627.
[33]Chen L, Orr CE, Wang T. Prevalence of histological features resembling autoimmune pancreatitis in neoplastic pancreas resections. Histopathology,2020,77:673-677.
[34]商伟芳,朱玲玲,李瑶,等.胰腺导管内乳头状黏液性肿瘤恶变继发自身免疫性胰腺炎样改变1例报告.中国微创外科杂志,2025,25(7):442-445.
[35]Wang H, Yao L, Wang L, et al. Focal IgG4�瞨elated autoimmune pancreatitis with distal choledochal adenocarcinoma: a rare case report. BMC Gastroenterol,2021,21:421.
[36]Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology,2017,17:1-6.
[37]Lanzillotta M, Vujasinovic M, L�塰r JM, et al. Update on autoimmune pancreatitis and IgG4�瞨elated disease. United European Gastroenterol J,2025,13(1):107-115.
[38]Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020. J Gastroenterol,2022,57(4):225-245.
[39]Tu J, Huang Z, Wang Y, et al. Transcriptome analysis of the procession from chronic pancreatitis to pancreatic cancer and metastatic pancreatic cancer. Sci Rep,2021,11:3409.
[40]Kiyoshita Y, Ishii Y, Serikawa M, et al. Relapse rate and predictors of relapse after cessation of glucocorticoid maintenance therapy in type 1 autoimmune pancreatitis: a multicenter retrospective study. BMC Gastroenterol,2023,23:295.
[41]Tsujimae M, Masuda A, Takagi M, et al. Relapse and side effects of steroid therapy beyond 3 years in autoimmune pancreatitis: a multicenter retrospective study. Pancreatology,2024,24(2):223-231.
[42]Ikeura T, Detlefsen S, Zamboni G, et al. Retrospective comparison between preoperative diagnosis by International Consensus Diagnostic Criteria and histological diagnosis in patients with focal autoimmune pancreatitis who underwent surgery with suspicion of cancer. Pancreas,2014,43(5):698-703.
[43]Liu B, Tang N, Yao Y, et al. Steroid treatment response combined with serological mark in differentiating type��1 autoimmune pancreatitis from pancreatic cancer. Medicine,2022,101(45):e31660.
[44]Barresi L, Tacelli M, Crinò SF, et al. Multicentric Italian survey on daily practice for autoimmune pancreatitis: clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. United European Gastroenterol J,2020,8(6):705-715.
[45]Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long�瞭erm maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut,2017,66(3):487-494.
[46]Le Cosquer G, Ribes D, Faguer S, et al. Long�瞭erm follow�瞮p and immunomonitoring of relapsing type 1 autoimmune pancreatitis treated with rituximab. Pancreas,2022,51(5):452-462.
[47]De Marchi G, de Pretis N, Gabrieletto EM, et al. Rituximab as maintenance therapy in type 1 autoimmune pancreatitis: an Italian experience. Pancreas,2021,50(10):1363-1367.
[48]Loganathan P, Siby N, Mohan BP, et al. Efficacy of rituximab in autoimmune�瞞ediated IgG4 pancreaticobiliary disease: a systematic review and meta�瞐nalysis. J Clin Gastroenterol,2025,59(7):678-684.
[49]Soliman H, Vullierme MP, Maire F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: rituximab is safe and effective. United European Gastroenterol J,2019,7(8):1073-1083.
[50]Nikolic S, Ghorbani P, Pozzi Mucelli R, et al. Surgery in autoimmune pancreatitis. Dig Surg,2022,39(1):32-41.
[51]Zavrtanik H, Toma�恑 A. Is surgery in autoimmune pancreatitis always a failure? Medicina (Kaunas),2023,59(2):193.
[52]Dickerson LD, Farooq A, Bano F, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging. World J Surg,2019,43(6):1604-1611.
[53]Macinga P, Pulkertova A, Bajer L, et al. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass. World J Gastroenterol,2017,23(12):2185-2193.
[54]Clark CJ, Morales�睴yarvide V, Zaydfudim V, et al. Short�瞭erm and long�瞭erm outcomes for patients with autoimmune pancreatitis after pancreatectomy: a multi�瞚nstitutional study. J Gastrointest Surg,2013,17(5):899-906.
[55]Poddighe D. Autoimmune pancreatitis and pancreatic cancer: epidemiological aspects and immunological considerations. World J Gastroenterol,2021,27(25):3825-3836.
[56]Kurita Y, Kubota K, Fujita Y, et al. IgG4�瞨elated pancreatobiliary diseases could be associated with onset of pancreatobiliary cancer: a multicenter cohort study. J Hepatobiliary Pancreat Sci,2024,31:173-182.
[57]Takikawa T, Kikuta K, Sano T, et al. Maintenance steroid therapy is associated with decreased risk of malignancy and better prognosis of patients with autoimmune pancreatitis: a multicenter cohort study in Japan. Pancreatology,2024,24:335-342.
[58]Ishikawa T, Kawashima H, Ohno E, et al. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. J Gastroenterol Hepatol,2020,35(12):2224-2231.
[59]Buijs J, Cahen DL, van Heerde MJ, et al. The long term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas,2015,44(7):1065-1071.
[60]Okamoto A, Watanabe T, Kamata K, et al. Recent updates on the relationship between cancer and autoimmune pancreatitis. Intern Med,2019,58(11):1533-1539.
[61]Gallo C, Dispinzieri G, Zucchini N, et al. Autoimmune pancreatitis: Cornerstones and future perspectives. World J Gastroenterol,2024,30(8):817-832.
[62]Kamisawa T, Tsuruta K, Okamoto A, et al. Frequent and significant K�瞨as mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas,2009,38(8):890-895.
[63]Gupta R, Khosroshahi A, Shinagare S, et al. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma?: a retrospective analysis of pancreatic resections. Pancreas,2013,42(3):506-510.
[64]Kinugawa Y, Uehara T, Sano K, et al. Methylation of tumor suppressor genes in autoimmune pancreatitis. Pancreas,2017,46(5):614-618.
[65]Liu L, Aleksandrowicz E, Sch�塶siegel F, et al. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP��1. Cell Death Dis,2017,8:e3064.
[66]Asano J, Watanabe T, Oguchi T, et al. Association between immunoglobulin G4�瞨elated disease and malignancy within 12 years after diagnosis: an analysis after longterm followup. The Journal of Rheumatology,2015,42(11):2135-2142.
[67]Sardi�媋 González C, Martínez Vivero C, López Castro J. Paraneoplastic syndromes review: the great forgotten ones. Crit Rev Oncol Hematol,2022,174:103676.
[68]Gonda M, Kobayashi T, Notohara K, et al. A case of pancreatic ductal adenocarcinoma concomitant with IgG4�瞨elated disease in the pancreas and the stomach. Clin J Gastroenterol,2023,16(5):785-790.